SGS Becomes Medidata Rave Accredited Partner
SGS Life Science Services announced that its Biometrics group became a Medidata Rave accredited partner.
SGS Life Science Services, a pharmaceutical clinical and bioanalytical contract solutions provider, announced that its Biometrics group, one of the largest European data management, statistics and medical writing teams, became a Medidata Rave® accredited partner. Medidata Rave captures, manages and reports clinical research data, designed to help life science companies optimize their research investments, by efficiently streamlining the clinical trial process.
Medidata’s accreditation program for Rave is an in-depth qualification program through both build and process enablement tracks, with the aim for partners to provide end-user training, user and site administration, study build, reporting, outputs and migration services. Implementing Rave studies since 2010, and a Medidata CTMS™ partner for more than five years, SGS Life Science Services has robust and fully optimized processes in place, allowing for short set-up timelines that support the clinical team’s challenge of getting First Patient In (FPI) on time.
Read the full release here.
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
